[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Co-Diagnostics Inc (CODX)

Co-Diagnostics Inc (CODX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,054
  • Shares Outstanding, K 3,685
  • Annual Sales, $ 620 K
  • Annual Income, $ -46,900 K
  • EBIT $ -29 M
  • EBITDA $ -28 M
  • 60-Month Beta 2.87
  • Price/Sales 7.45
  • Price/Cash Flow N/A
  • Price/Book 0.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-6.91
  • Growth Rate Est. (year over year) +14,557.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9396 +19.20%
on 08/19/26
2.6088 -57.07%
on 07/22/26
-1.3200 (-54.10%)
since 07/20/26
3-Month
0.9396 +19.20%
on 08/19/26
13.5400 -91.73%
on 05/28/26
-1.2700 (-53.14%)
since 05/20/26
52-Week
0.9396 +19.20%
on 08/19/26
46.5000 -97.59%
on 10/27/25
-7.3340 (-86.75%)
since 08/20/25

Most Recent Stories

More News
Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

CODX : 1.1200 (+1.82%)
Co-Diagnostics Reports Second Quarter 2026 Financial Results

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion

CODX : 1.1200 (+1.82%)
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro ® instrument in decentralized point-of-care settings

CODX : 1.1200 (+1.82%)
Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY , July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.  (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 1.1200 (+1.82%)
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument

CODX : 1.1200 (+1.82%)
Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform

PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India

CODX : 1.1200 (+1.82%)
Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

SALT LAKE CITY , July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX)  ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development...

CODX : 1.1200 (+1.82%)
Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs

CODX : 1.1200 (+1.82%)
Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week

CODX : 1.1200 (+1.82%)
Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line

Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer  

CODX : 1.1200 (+1.82%)

Business Summary

Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests which are designed using the detection and/or analysis of nucleic acid molecules. It also uses proprietary technology...

See More

Key Turning Points

3rd Resistance Point 1.6972
2nd Resistance Point 1.5136
1st Resistance Point 1.3068
Last Price 1.1200
1st Support Level 0.9164
2nd Support Level 0.7328
3rd Support Level 0.5260

See More

52-Week High 46.5000
Fibonacci 61.8% 29.0959
Fibonacci 50% 23.7198
Fibonacci 38.2% 18.3437
Last Price 1.1200
52-Week Low 0.9396

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.